XML 52 R59.htm IDEA: XBRL DOCUMENT v2.4.1.9
Other Intangible Assets, Net (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Dec. 31, 2013
Intangible Assets (Excluding Goodwill) [Line Items]        
Amortized intangible assets $ 9,779.0us-gaap_FiniteLivedIntangibleAssetsGross   $ 4,846.9us-gaap_FiniteLivedIntangibleAssetsGross  
Other intangible assets, gross 11,503.5us-gaap_IntangibleAssetsGrossExcludingGoodwill   6,396.9us-gaap_IntangibleAssetsGrossExcludingGoodwill  
Less: Accumulated amortization (1,523.5)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization   (1,462.5)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization  
Other intangible assets, net 9,980.0us-gaap_IntangibleAssetsNetExcludingGoodwill 4,943.4us-gaap_IntangibleAssetsNetExcludingGoodwill 4,934.4us-gaap_IntangibleAssetsNetExcludingGoodwill 2,312.6us-gaap_IntangibleAssetsNetExcludingGoodwill
Other Disclosures        
Acquisitions 5,198.0shpgf_IntangibleAssetsExcludingGoodwillAcquiredDuringPeriod 2,854.0shpgf_IntangibleAssetsExcludingGoodwillAcquiredDuringPeriod    
Estimates of Annual Amortization        
2015 481us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths      
2016 481us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo      
2017 481us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree      
2018 481us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour      
2019 481us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive      
NPS Pharma and Meritage, Combined        
Other Disclosures        
Acquisitions 5,198.0shpgf_IntangibleAssetsExcludingGoodwillAcquiredDuringPeriod
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaAndMeritageTotalMember
     
Currently Marketed Products        
Intangible Assets (Excluding Goodwill) [Line Items]        
Amortized intangible assets 9,404.0us-gaap_FiniteLivedIntangibleAssetsGross
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= shpgf_AcquiredCurrentlyMarketedProductsMember
  4,816.9us-gaap_FiniteLivedIntangibleAssetsGross
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= shpgf_AcquiredCurrentlyMarketedProductsMember
 
Royalty rights        
Intangible Assets (Excluding Goodwill) [Line Items]        
Amortized intangible assets 375.0us-gaap_FiniteLivedIntangibleAssetsGross
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= us-gaap_OtherIntangibleAssetsMember
  30.0us-gaap_FiniteLivedIntangibleAssetsGross
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= us-gaap_OtherIntangibleAssetsMember
 
IPR&D        
Intangible Assets (Excluding Goodwill) [Line Items]        
Unamortized intangible assets 1,724.5us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= shpgf_AcquiredInProcessResearchAndDevelopmentMember
  1,550.0us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= shpgf_AcquiredInProcessResearchAndDevelopmentMember
 
IPR&D | Meritage        
Other Disclosures        
Acquisitions 175.0shpgf_IntangibleAssetsExcludingGoodwillAcquiredDuringPeriod
/ us-gaap_BusinessAcquisitionAxis
= shpgf_MeritagePharmaIncMember
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= shpgf_AcquiredInProcessResearchAndDevelopmentMember
     
Currently marketed products and royalty rights | NPS Pharma        
Other Disclosures        
Acquisitions $ 5,023.0shpgf_IntangibleAssetsExcludingGoodwillAcquiredDuringPeriod
/ us-gaap_BusinessAcquisitionAxis
= shpgf_NpsPharmaceuticalsIncMember
/ shpgf_IntangibleAssetsExcludingGoodwillByMajorClassAxis
= shpgf_CurrentlyMarketedProductsAndRoyaltyRightsMember